Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 10:33 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2665–2688 of 10,818 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Developmental Defect Clear all
Terminated Phase 2 Interventional Results available

Long-Term Study (AtDvance) to Evaluate GSK1070806 in Atopic Dermatitis.

NCT06447506
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
GSK1070806, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
6
States / cities
Fountain Valley, California • Pompano Beach, Florida • Fayetteville, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Nov 2, 2026, 10:33 PM EST
Completed Early Phase 1 Interventional

Angelman Syndrome (AS) Biomarker Study

NCT04103333
View directory record Official record
Conditions
Angelman Syndrome, Chromosome 15q Duplication (dup15q) Syndrome
Interventions
Lumbar Puncture, Blood Collection
Procedure
Lead sponsor
Biogen
Industry
Eligibility
Up to 50 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
5
States / cities
San Diego, California • Chicago, Illinois • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2022 · Synced Nov 2, 2026, 10:33 PM EST
Active, not recruiting Phase 3 Interventional

An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary Atresia

NCT05426733
View directory record Official record
Conditions
Biliary Atresia
Interventions
Odevixibat
Drug
Lead sponsor
Albireo, an Ipsen Company
Industry
Eligibility
Not listed
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
10
States / cities
Aurora, Colorado • Atlanta, Georgia • Indianapolis, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 2, 2026, 10:33 PM EST
Withdrawn No phase listed Observational

Optical Frequency Domain Imaging (OFDI) in Dermatology

NCT01438047
View directory record Official record
Conditions
Port Wine Stain
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 4, 2014 · Synced Nov 2, 2026, 10:33 PM EST
Completed Phase 3 Interventional Results available

A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F)

NCT03525548
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-445/TEZ/IVA, TEZ/IVA, IVA, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
28
States / cities
Tucson, Arizona • Little Rock, Arkansas • Long Beach, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Nov 2, 2026, 10:33 PM EST
Completed Phase 4 Interventional Results available

Cryoanalgesia vs. Epidural in the Nuss Procedure

NCT02721017
View directory record Official record
Conditions
Pectus Excavatum, Funnel Chest
Interventions
Cryoanalgesia, Thoracic epidural (ropivicaine, fentanyl)
Device · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
13 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Nov 2, 2026, 10:33 PM EST
Completed No phase listed Observational

Multisite Feeding Study: Home Surveillance and Feeding Strategies in Infants With Complex Single Ventricle

NCT00257517
View directory record Official record
Conditions
Congenital Disorders
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
Up to 30 Days
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Nov 2, 2026, 10:33 PM EST
Completed No phase listed Observational

Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors

NCT00001668
View directory record Official record
Conditions
Deafness, Kidney Diseases, Kidney Neoplasms, Neoplasms, Retinal Diseases
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Nov 2, 2026, 10:33 PM EST
Recruiting Phase 2 Interventional

Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis

NCT06747858
View directory record Official record
Conditions
Cystic Fibrosis, CFTR Gene Mutation
Interventions
ARCT-032
Biological
Lead sponsor
Arcturus Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
13
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Nov 2, 2026, 10:33 PM EST
Completed No phase listed Observational

Clinical and Genetic Studies on Holoprosencephaly

NCT00088426
View directory record Official record
Conditions
Holoprosencephaly, HPE, Developmental Delay Disorders, Brain Disorders
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
1 Month and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Nov 2, 2026, 10:33 PM EST
Completed Phase 2 Interventional

RCT of High- vs. Standard-Calorie Formula for Methadone-Exposed Infants

NCT02178189
View directory record Official record
Conditions
Neonatal Abstinence Syndrome
Interventions
High Calorie Infant formula, Standard Calorie Infant Formula
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
1 Day to 3 Days
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 30, 2014 · Synced Nov 2, 2026, 10:33 PM EST
Recruiting Phase 2 Interventional

Treatment of Neonatal Encephalopathy With Oral Sildenafil Suspension to Repair Brain Injury Secondary to Birth Asphyxia

NCT06098833
View directory record Official record
Conditions
Neonatal Encephalopathy
Interventions
Sildenafil, Ora-Blend
Drug
Lead sponsor
Pia Wintermark
Other
Eligibility
0 Minutes to 48 Hours
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Nov 2, 2026, 10:33 PM EST
Completed Phase 2 Interventional Results available

Ganaxolone Treatment in Children With Fragile X Syndrome

NCT01725152
View directory record Official record
Conditions
Fragile x Syndrome
Interventions
Ganaxolone, Placebo
Drug
Lead sponsor
Marinus Pharmaceuticals
Industry
Eligibility
6 Years to 17 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Nov 2, 2026, 10:33 PM EST
Terminated No phase listed Observational

Evaluating Right Ventricular (RV) Size and Function Using the Upper Valley RV Algorithm and Novel Imaging Modalities

NCT03935178
View directory record Official record
Conditions
Pulmonary Hypertension, Valvular Heart Disease, Congenital Heart Disease, Congestive Heart Failure, Pulmonary Embolism, Acute Coronary Syndrome
Interventions
Measuring Right Ventricular Size and Function
Diagnostic Test
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Apr 6, 2022 · Synced Nov 2, 2026, 10:33 PM EST
Not listed No phase listed Observational

International PFO Consortium

NCT00859885
View directory record Official record
Conditions
Stroke, Transient Ischemic Attack
Interventions
Antithrombotic treatment, percutaneous device closure of PFO
Drug · Device
Lead sponsor
Insel Gruppe AG, University Hospital Bern
Other
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2021
U.S. locations
3
States / cities
Boston, Massachusetts • Springfield, Massachusetts • Tyler, Texas
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Nov 2, 2026, 10:33 PM EST
Completed Phase 1Phase 2 Interventional Results available

Rivastigmine Study in Adolescents With Down Syndrome

NCT01084135
View directory record Official record
Conditions
Down Syndrome
Interventions
Rivastigmine, Liquid Placebo
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
10 Years to 17 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
Baltimore, Maryland • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Nov 2, 2026, 10:33 PM EST
Completed Phase 2 Interventional

An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Prader-Willi Syndrome

NCT01818921
View directory record Official record
Conditions
Obesity, Over-weight, Prader-Willi Syndrome
Interventions
ZGN-440 sterile diluent, 1.2 mg ZGN-440 for injectable suspension, 1.8 mg ZGN-440 for injectable suspension
Drug
Lead sponsor
Zafgen, Inc.
Industry
Eligibility
16 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 18, 2016 · Synced Nov 2, 2026, 10:33 PM EST
Completed Phase 3 Interventional

Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

NCT04227106
View directory record Official record
Conditions
Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa
Interventions
EB-101
Biological
Lead sponsor
Abeona Therapeutics, Inc
Industry
Eligibility
6 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Redwood City, California • Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 5, 2022 · Synced Nov 2, 2026, 10:33 PM EST
Completed Phase 3 Interventional Results available

Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015

NCT00984126
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia A
Interventions
turoctocog alfa
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
6 Months to 70 Years · Male only
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
13
States / cities
Phoenix, Arizona • Long Beach, California • Tampa, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2017 · Synced Nov 2, 2026, 10:33 PM EST
Completed No phase listed Observational

Defining the Genetic Etiology of Suppurative Lung Disease in Children and Adults

NCT04702243
View directory record Official record
Conditions
Primary Ciliary Dyskinesia, Primary Immune Deficiency, Kartagener Syndrome
Interventions
Genetic Testing for PCD or PID, Unaffected Family Member Genetic Testing
Diagnostic Test · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
5 Years to 45 Years
Enrollment
436 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
6
States / cities
Palo Alto, California • Aurora, Colorado • Bethesda, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Nov 2, 2026, 10:33 PM EST
Terminated Phase 2 Interventional Results available

Phase 2a Extension Study of Ataluren (PTC124) in Duchenne Muscular Dystrophy (DMD)

NCT00759876
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Ataluren
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
3
States / cities
Cincinnati, Ohio • Philadelphia, Pennsylvania • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 29, 2020 · Synced Nov 2, 2026, 10:33 PM EST
Completed Phase 2Phase 3 Interventional Results available

A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL

NCT03019185
View directory record Official record
Conditions
Alport Syndrome
Interventions
Placebo Oral Capsule, Bardoxolone Methyl
Drug
Lead sponsor
Biogen
Industry
Eligibility
12 Years to 60 Years
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Nov 2, 2026, 10:33 PM EST
Recruiting Phase 2 Interventional

Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84 in Patients With Cystic Fibrosis

NCT06429176
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
SPL84, Placebo
Drug · Other
Lead sponsor
SpliSense Ltd.
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Los Angeles, California • Denver, Colorado • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Nov 2, 2026, 10:33 PM EST
Completed No phase listed Observational

Clinical Studies of Progeria

NCT00094393
View directory record Official record
Conditions
Progeria
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
6 Months to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 15, 2019 · Synced Nov 2, 2026, 10:33 PM EST